# Chai's one-shot drug discovery performance

**Created:** 12/16/2025 8:05:33  
**Updated:** 12/16/2025 8:19:05  
**Exported:** 12/16/2025 8:20:32  
**Link:** [https://claude.ai/chat/8c1928ba-c764-4271-be8d-32d00c7f3fc6](https://claude.ai/chat/8c1928ba-c764-4271-be8d-32d00c7f3fc6)  

## Prompt:
12/16/2025, 8:05:38 AM

help me understand what is so differentaited about chai's approach. does the % performance on one-shot (16% hit rate) really matter for drug development?? how did they accomplsih this? https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf



## Response:
12/16/2025, 8:07:00 AM

````plaintext
Thought process: Examined paper to clarify Chai's differentiation and performance implications.

The user is asking about a specific paper from biorxiv about Chai's approach. They want to understand:
1. What's differentiated about Chai's approach
2. Whether the 16% one-shot hit rate matters for drug development
3. How they accomplished this

Let me fetch this paper to understand what they're talking about.
````

I'll fetch that paper to give you a proper breakdown of what Chai is claiming and whether it actually matters for drug discovery.

````plaintext
Web Fetch: Failed to fetch: https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf
````

````plaintext
Thought process: Attempted alternative retrieval method for inaccessible document.

The PDF didn't load directly. Let me try fetching the main page for this paper instead.
````

````plaintext
Web Fetch: Failed to fetch: https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1
````

````plaintext
Thought process

Let me search for this paper specifically.
````

````plaintext
Web Search: Chai Discovery biorxiv 2025 one-shot hit rate drug discovery
````

> **Zero-shot antibody design in a 24-well plate | bioRxiv** [biorxiv.org](https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1)
>
> **Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery** [businesswire.com](https://www.businesswire.com/news/home/20251214931432/en/Chai-Discovery-Announces-$130-Million-Series-B-To-Transform-Molecular-Discovery)
>
> **Biorxiv** [biorxiv.org](https://www.biorxiv.org/content/10.1101/2025.07.05.663018v1.full.pdf)
>
> **Chai-1: Decoding the molecular interactions of life | bioRxiv** [biorxiv.org](https://www.biorxiv.org/content/10.1101/2024.10.10.615955v1)
>
> **GitHub - chaidiscovery/chai-lab: Chai-1, SOTA model for biomolecular structure prediction** [github.com](https://github.com/chaidiscovery/chai-lab)
>
> **OpenAI-Backed Chai Discovery Raises $130M to Tackle "Undruggable" Targets with Generative AI** [hitconsultant.net](https://hitconsultant.net/2025/12/15/openai-backed-chai-discovery-raises-130m-to-tackle-undruggable-targets-with-generative-ai/)
>
> **Chai Discovery Team Releases Chai-2: AI Model Achieves 16% Hit Rate in De Novo Antibody Design - MarkTechPost** [marktechpost.com](https://www.marktechpost.com/2025/07/05/chai-discovery-team-releases-chai-2-ai-model-achieves-16-hit-rate-in-de-novo-antibody-design/)
>
> **Chai-2 Redefines Antibody Discovery: AI-Driven De Novo Design with Industry-Leading Hit Rates | Medvolt.ai** [medvolt.ai](https://www.medvolt.ai/blog/chai-2-de-novo-antibody-design-ai-breakthrough)
>
> **OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation | TechCrunch** [techcrunch.com](https://techcrunch.com/2025/12/15/openai-backed-biotech-firm-chai-discovery-raises-130m-series-b-at-1-3b-valuation/)
>
> **Chai-1: Decoding the molecular interactions of life Chai Discovery team** [biorxiv.org](https://www.biorxiv.org/content/10.1101/2024.10.10.615955v1.full.pdf)
>
````plaintext
Thought process

Now I have a good understanding of what Chai-2 is claiming. Let me search for more context on how traditional antibody discovery works and what prior computational methods achieved to give better context on the "so what" for a healthcare VC.
````

````plaintext
Web Search: traditional antibody discovery hit rate phage display hybridoma screening comparison computational
````

> **Hybridoma VS Display : The Fight Of The Century - Innovative antibodies against haptens and transmembrane proteins** [synabs.be](https://www.synabs.be/2019/11/25/hybridoma-vs-display-the-fight-of-the-century/)
>
> **Advances in antibody phage display technology - ScienceDirect** [sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1359644622001738)
>
> **Phage Display Libraries for Antibody Therapeutic Discovery and Development** [mdpi.com](https://www.mdpi.com/2073-4468/8/3/44)
>
> **Phage Display vs. Hybridoma Technology: Revolutionizing Antibody Discovery with High-Diversity Libraries - Creative Biolabs** [biotechphage.com](https://www.biotechphage.com/phage-display-vs-hybridoma-technology.html)
>
> **Phage Display vs. Hybridoma Technology - Creative Biolabs** [creative-biolabs.com](https://www.creative-biolabs.com/phage-display-vs-hybridoma.html)
>
> **Hybridoma vs Phage Display for Monoclonal Antibody Production: Which Technique for Which Purpose? | Technology Networks** [technologynetworks.com](https://www.technologynetworks.com/drug-discovery/blog/hybridoma-vs-phage-display-for-monoclonal-antibody-production-which-technique-for-which-purpose-314741)
>
> **Phage Display vs. Hybridoma for mAb Production - ProteoGenix US** [proteogenix.science](https://us.proteogenix.science/scientific-corner/antibody-production/phage-display-vs-hybridoma-for-mab-production/)
>
> **Phage Display Antibody Discovery: Production & Applications | Danaher Life Sciences** [danaher.com](https://lifesciences.danaher.com/us/en/library/phage-display.html)
>
> **Hit Generation and Screening** [genscript.com](https://www.genscript.com/hit-generation-screening.html)
>
> **Phage Display Libraries for Antibody Therapeutic Discovery and Development - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6784186/)
>
````plaintext
Thought process

Now I have a good understanding of the landscape. Let me also search for comparisons to other computational antibody design approaches like RFdiffusion/RFdesign from Baker Lab to give better context on the "100-fold improvement" claim.
````

````plaintext
Web Search: RFdiffusion antibody design experimental hit rate Baker lab computational de novo
````

> **Atomically accurate de novo design of antibodies with RFdiffusion - PMC** [nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10983868/)
>
> **Designing antibodies with RFdiffusion • Baker Lab** [bakerlab.org](https://www.bakerlab.org/2025/02/28/designing-antibodies-with-rfdiffusion/)
>
> **Atomically accurate de novo design of antibodies with RFdiffusion | Nature** [nature.com](https://www.nature.com/articles/s41586-025-09721-5)
>
> **Atomically accurate de novo design of antibodies with RFdiffusion - PubMed** [nih.gov](https://pubmed.ncbi.nlm.nih.gov/38562682/)
>
> **Atomically accurate de novo design of antibodies with RFdiffusion | bioRxiv** [biorxiv.org](https://www.biorxiv.org/content/10.1101/2024.03.14.585103v2)
>
> **Computational De Novo Design of Antibodies and Nanobodies** [tamarind.bio](https://www.tamarind.bio/blog/de-novo-antibody-nanobody-vhh-scfv-rfdiffusion)
>
> **How a fine-tuned RFdiffusion network can design VHHs | The Antibody Society posted on the topic | LinkedIn** [linkedin.com](https://www.linkedin.com/posts/the-antibody-society_atomically-accurate-de-novo-design-of-single-domain-activity-7175811605207642112-lQs4)
>
> **Nobel winner’s lab notches another breakthrough: AI-designed antibodies that hit their targets** [geekwire.com](https://www.geekwire.com/2025/nobel-winners-lab-notches-another-breakthrough-ai-designed-antibodies-that-hit-their-targets/)
>
> **De novo design of protein structure and function with RFdiffusion | Nature** [nature.com](https://www.nature.com/articles/s41586-023-06415-8)
>
> **Design de novo antibody-antigen interactions with RFantibody - Levitate Bio** [levitate.bio](https://levitate.bio/design-de-novo-antibody-antigen-interactions-with-rfantibody/)
>
````plaintext
Thought process: Synthesized Chai-2's differentiation, performance metrics, and technical mechanisms comprehensively.

Now I have a good understanding. Let me synthesize this for the healthcare VC. The key points:

1. **What Chai-2 claims:**
- 16% hit rate for de novo antibody design (across all targets)
- 50% of targets had at least one hit (26/52 targets)
- Tested ≤20 designs per target on 52 novel targets (none with pre-existing binders in PDB)
- 68% success rate for miniprotein design with picomolar affinities
- Turnaround from AI design to wet-lab validation in under 2 weeks
- Zero-shot (no prior binders needed)

2. **Comparison to prior methods:**
- Prior computational methods: <0.1% hit rates (thus the "100-fold improvement" claim)
- RFdiffusion/Baker Lab: Still requires yeast display screening (not zero-shot), affinity maturation needed, tested 95-10k designs to find hits
- Traditional phage display: Requires 10^10 library, multiple rounds of panning, weeks to months
- Hybridoma: 6-8 months, requires animal immunization

3. **Does 16% matter?**
Yes, this is significant because:
- At 16% hit rate with 20 designs, probability of at least one hit is 1-(0.84)^20 = ~97% per target
- This enables "one-shot" discovery - no iterative screening rounds needed
- Changes the economics dramatically: from screening millions to screening 24 (24-well plate)
- Time compression: 2 weeks vs. months
- Cost compression: mentioned one target that cost >$5M in traditional R&D was solved by Chai-2 in hours of compute

4. **How did they accomplish this?**
- Chai-2 is a multimodal generative model building on Chai-1 (their structure prediction foundation model)
- Integrates all-atom generative design with folding/structure prediction


- 2x better antibody-antigen complex structure prediction vs Chai-1
- Trained on structural data to understand antibody-antigen interfaces
- Can be "prompted" with target epitope information

5. **Key differentiation vs RFdiffusion:**
I see a critical advantage in Chai-2's approach. Unlike RFdiffusion, which still requires extensive screening, Chai-2 offers true zero-shot design. They can generate high-affinity binders directly, achieving picomolar to low nanomolar binding strengths without iterative optimization. The ability to incorporate epitope information and predict complex structures with twice the previous accuracy sets a new benchmark in computational antibody design.

Requires additional optimization through techniques like OrthoRep to reach single-digit nanomolar affinities. The platform appears more streamlined compared to RFdiffusion's multi-step pipeline.

6. **Caveats/Potential Limitations:**
The research comes with important cautionary notes. As a company-generated preprint, there's an inherent potential for bias. Their validation metrics seem relatively permissive, with binding measurements just above background noise. While affinity looks promising, deeper characterization of antibody developability remains unexplored. The lack of direct comparative testing against RFdiffusion and small sample sizes for challenging targets suggest more rigorous validation is needed.
````

Now I have the full picture. Let me break this down with the "so what" you're looking for.

---

## Chai-2: What's Actually Differentiated

**The Core Claim**

Chai-2 achieves a 16% hit rate in fully de novo antibody design, representing an over 100-fold improvement compared to previous computational methods. They tested ≤20 antibodies/nanobodies per target across 52 diverse targets—crucially, none of these targets have a preexisting antibody or nanobody binder in the Protein Data Bank.

**Does 16% Actually Matter?**

Yes—and here's the math that makes it investable:

At a 16% per-design hit rate with 20 designs tested, your probability of finding *at least one* binder is ~97% per target. This is why they got at least one successful hit for 50% of targets (26/52)—and many of those failures were likely hard-to-drug targets where the biology itself is challenging.

The real unlock is **the denominator change**:
- Traditional phage display: Screen 10⁹-10¹¹ library members
- Prior computational methods: <0.1% hit rate → need to test thousands-millions of designs
- RFdiffusion (Baker Lab): Still requires yeast display screening of 95-10,000 designs, plus affinity maturation
- **Chai-2**: ≤20 designs in a 24-well plate, no follow-on screening

One target costing >$5M in traditional R&D was solved by Chai-2 in hours of compute and validated in two weeks.

**How They Did It**

Chai-2 builds on Chai-1 (their AlphaFold3-competitive structure prediction model) but adds:

1. **Integrated generative design**: Chai-2 integrates an all-atom generative design module and a folding model that predicts antibody-antigen complex structures with double the accuracy of its predecessor, Chai-1.

2. **True zero-shot capability**: The system operates in a zero-shot setting, generating sequences for antibody modalities like scFvs and VHHs without requiring prior binders.

3. **Direct affinity output**: Many binders showed picomolar to low-nanomolar dissociation constants (KDs), indicating high-affinity interactions. This is critical—RFdiffusion designs typically need OrthoRep affinity maturation to get to single-digit nM.

**Chai-2 vs. RFdiffusion (Baker Lab) – Head-to-Head Positioning**

| Dimension | RFdiffusion | Chai-2 |
|-----------|-------------|--------|
| Screening needed | Yes (yeast display, 95-10k designs) | No (≤20 designs tested directly) |
| Initial affinity | Modest; needs maturation | Picomolar-nM out of the box |
| Workflow | Multi-step (RFdiffusion → ProteinMPNN → RF2 validation → yeast display → OrthoRep) | End-to-end single model |
| Structural validation | ✓ cryo-EM confirmed | ✓ BLI + follow-up validation |
| Open source | Yes (MIT license) | No (commercial) |

---

## The Real "So What" for Drug Development

**1. Timeline Compression**
Chai-2 effectively compresses timelines from months to days, making zero-shot discovery feasible. Traditional biologics discovery is 6-18 months to validated lead. Chai claims ~2 weeks.

**2. Economics Shift**
The business model implication is massive. If you can reliably generate binders in a 24-well plate instead of running million-dollar screening campaigns, you change the fundamental economics of biologics discovery. This is why they just announced a $130 million Series B at a $1.3B valuation.

**3. Hard-to-Drug Targets Become Tractable**
Notably, Chai-2 produced hits for hard targets such as TNFα, which has historically been intractable for in silico design.

**4. Developability (The Real Test)**
The claim extends beyond just binding: the company showed their latest models can now design molecules with important "developability" properties and tackle "hard-to-drug" targets that have historically been challenging for traditional techniques.

---

## Caveats to Watch

1. **Conflict of interest**: This is company-authored preprint, not independent validation
2. **BLI threshold is permissive**: binding-positive curve signature while requiring that the signal is both greater than 0.1 nm above background and greater than 300% of background—this is a relatively generous definition of "hit"
3. **Developability beyond affinity**: Aggregation, viscosity, immunogenicity, manufacturability—less characterized
4. **No head-to-head with RFdiffusion**: Same targets weren't tested across platforms
5. **Sample size**: 52 targets is meaningful but still limited

---

## Investment Thesis Question

The key diligence question: **Is Chai building a durable moat, or will open-source (RFdiffusion) catch up?**

Baker Lab's approach is open (MIT license), and filtering by AF3 iPTM should increase success rates—suggesting the gap may narrow. But Chai's integration and commercial focus could maintain a lead in practical drug discovery applications.

The 16% number matters because it crosses a threshold where computational biology becomes the *primary* discovery engine rather than a filter for experimental screening. That's a paradigm shift.



## Prompt:
12/16/2025, 8:18:11 AM

what would be the bear and bull case for this specific approach (assuming you believe in AI for bio)



## Response:
12/16/2025, 8:19:05 AM

````plaintext
Thought process: Weighed competitive risks and rewards for biotech approach.

The user wants me to think through bear and bull cases for Chai's specific approach, assuming the broader thesis of AI for bio is valid. This is a classic VC framing - they want to understand the risk/reward profile of this particular company and approach versus alternatives.

Let me think through both sides carefully, drawing on what I know about the competitive landscape, technical details, and business model implications.
````

Great framing—let's assume AI-driven drug discovery is real and the question is whether *Chai specifically* wins.

---

## Bull Case: Chai Becomes the "Design Suite" for Biologics

**1. Integration Is the Moat, Not Any Single Model**

The biologics workflow today is fragmented: target ID → epitope mapping → library design → screening → hit validation → affinity maturation → developability optimization → manufacturing handoff. Each step involves different vendors, different data formats, different failure modes.

Chai's thesis is that a unified foundation model learns the *joint distribution* of structure, binding, and developability—not just structure prediction. If true, the compounding advantage is enormous:
- Every pharma partnership generates proprietary training data
- Model improves on edge cases (hard targets, novel modalities)
- Switching costs accumulate as workflows standardize around their platform

**2. The 16% Number Is Actually Conservative**

At 50% of *novel, never-before-drugged* targets getting at least one hit, you're already at commercial viability. But consider the trajectory:
- Chai-1 (Oct 2024): Structure prediction, AlphaFold3-competitive
- Chai-2 (July 2025): 16% hit rate, zero-shot antibody design
- Chai-3 (2026?): If hit rates climb to 30-40% with multi-objective optimization (affinity + developability + manufacturability), you've essentially solved the biologics design problem

The rate of improvement matters more than the current snapshot. They're shipping major capability jumps every 6-9 months.

**3. Pharma Incentives Align for Premium Pricing**

A single failed Phase I biologics program costs $50-100M. If Chai can deliver validated leads 10x faster with higher confidence, the willingness to pay is substantial—likely $1-5M per target for a "hit-to-lead" package. At 50-100 programs/year across big pharma, that's a $500M+ TAM just for lead generation, before you count platform licensing, co-development deals, or building their own pipeline.

**4. Miniproteins + Beyond Antibodies = Platform Expansion**

The 68% hit rate on miniprotein design is arguably more impressive than antibodies. Miniproteins are:
- Smaller (easier to manufacture, better tissue penetration)
- More stable (no cold chain issues)
- Novel IP (less crowded than mAb space)

If Chai can generalize to macrocycles, peptides, and eventually small molecules, they become a true "molecular design OS"—not just an antibody company.

**5. Talent Density + Capital = Execution Edge**

The team includes ex-Meta AI, ex-DeepMind researchers. $225M+ raised with OpenAI, Thrive, General Catalyst backing. In a winner-take-most market, the ability to attract top ML talent and move fast compounds quickly.

---

## Bear Case: Chai Is a Feature, Not a Platform

**1. Open Source Catches Up—Fast**

RFdiffusion is MIT licensed. AlphaFold3 weights are now available. The Baker Lab publishes everything. Academic labs and well-funded biotechs (Xaira, Generate, etc.) can replicate and iterate.

The key vulnerability: Chai's advantage is *integration and polish*, not fundamental scientific breakthrough. If the core algorithms are commoditized, Chai becomes a services business competing on execution—not a high-margin software platform.

Timeline to worry: If RFdiffusion + AF3 filtering achieves 10%+ hit rates in independent academic validation within 12-18 months, Chai's moat erodes significantly.

**2. The 16% Number May Not Generalize**

Digging into the methodology:
- BLI is a binding assay, not a functional assay. A "hit" that binds may not neutralize, agonize, or have therapeutic effect
- 52 targets is statistically limited—could be selection bias toward easier epitopes
- No head-to-head with traditional methods on *the same targets*
- Company-authored, no independent replication yet

The real test: What happens when Novartis or Roche runs this on their internal hard-to-drug targets where they've already failed? If hit rates drop to 2-5%, the value prop changes.

**3. Developability Is Where Biologics Programs Die**

Binding is table stakes. Programs fail on:
- **Aggregation/viscosity**: Can't formulate at therapeutic concentrations
- **Immunogenicity**: Patients develop anti-drug antibodies
- **Expression yield**: Manufacturing economics don't work
- **Stability**: Shelf life and cold chain requirements
- **Polyspecificity**: Off-target binding creates safety issues

Chai claims "developability" but hasn't published rigorous data on these parameters. If their designs bind well but fail downstream, they're just generating more expensive garbage to kill later.

**4. Business Model Risk: Asset vs. Platform**

Two paths for AI bio companies:
1. **Platform play**: License technology, take milestones, don't own assets
2. **Asset play**: Build internal pipeline, capture drug economics

Platform play = lower risk, lower return, but defensible if you're the standard
Asset play = huge upside if drugs work, but you're competing with Lilly's $10B R&D budget

Chai seems to be hedging both ways. But that's capital-intensive and strategically unfocused. If they build a pipeline, they need $500M+ more for clinical development. If they stay platform-only, they need pharma to adopt at scale—and pharma moves slowly.

**5. The "Zero-Shot" Claim Is Misleading**

"Zero-shot" in Chai's framing means "no prior binder to this specific target." But:
- The model was trained on all known antibody-antigen complexes
- It's not designing truly novel binding mechanisms—it's interpolating from training data
- Targets with no structural homologs to training data may still fail

This matters because the truly valuable targets (novel biology, unprecedented mechanisms) are exactly where training data is sparse. The model may excel at "more of the same" but struggle with genuine novelty.

**6. Regulatory and Validation Overhead Doesn't Disappear**

Even if Chai delivers perfect leads, pharma still needs to:
- Validate binding independently
- Run functional assays
- Do tox/safety studies
- Manufacture at scale
- Run clinical trials

The *time-to-IND* compression is real, but the *time-to-approval* is still 7-10 years dominated by clinical phases. Chai accelerates maybe 10-15% of the total timeline—meaningful but not transformative for the overall drug development equation.

---

## Summary Matrix

| Factor | Bull | Bear |
|--------|------|------|
| **Moat** | Integration + data flywheel | Open source catches up |
| **Hit rate** | 16% is floor, will improve to 30%+ | Doesn't generalize to hard targets |
| **Developability** | Multi-objective optimization coming | Binding ≠ druggability |
| **Business model** | Platform standard for biologics | Feature, not company |
| **Timing** | First-mover in zero-shot design | Pharma adoption is slow |
| **Competition** | Talent + capital advantage | Baker Lab, Xaira, Generate all credible |

---

## The Key Swing Factor

**Can Chai demonstrate that model-designed antibodies have equivalent or better developability profiles than traditional discovery—at scale, across diverse targets, validated by independent pharma partners?**

If yes: $10B+ outcome (becomes the biologics design standard)
If no: $500M-1B outcome (good services business, eventual acquisition)

The next 18 months of external validation data will tell you which case is playing out.





---
Powered by [Claude Exporter](https://www.claudexporter.com)